title: Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints.
authors.affiliation: National Center for Health Research, Washington, DC.
authors.forename: Tracy
authors.initials: T
authors.lastname: Rupp
authors.affiliation: National Center for Health Research, Washington, DC.
authors.forename: Diana
authors.initials: D
authors.lastname: Zuckerman
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000494:pharmacology*; D015415:Biomarkers; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D016527:Drug Costs; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000523:psychology; D011788:Quality of Life; D015996:Survival Rate / Q000639:trends; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers